Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 2
1989 2
1990 5
1991 3
1993 5
1994 1
1996 4
1997 4
1998 1
2000 1
2001 1
2002 2
2003 3
2004 2
2006 2
2007 3
2008 1
2010 1
2011 4
2012 2
2013 2
2014 2
2016 2
2017 2
2018 3
2019 2
2021 1
2022 1
2023 4
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of mifepristone.
Heikinheimo O. Heikinheimo O. Clin Pharmacokinet. 1997 Jul;33(1):7-17. doi: 10.2165/00003088-199733010-00002. Clin Pharmacokinet. 1997. PMID: 9250420
The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is essential for the antagonistic properties of mifepristone. The pharmacokinetics of mifepristone are characterised by rapid absorption, a long half-life of 25 to 30 hours an …
The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is essential for the antagonistic properties of mifep …
Pharmacokinetics and Anti-Tumor Efficacy of PEGylated Liposomes Co-Loaded with Cisplatin and Mifepristone.
Ocaña-Arakachi K, Martínez-Herculano J, Jurado R, Llaguno-Munive M, Garcia-Lopez P. Ocaña-Arakachi K, et al. Pharmaceuticals (Basel). 2023 Sep 22;16(10):1337. doi: 10.3390/ph16101337. Pharmaceuticals (Basel). 2023. PMID: 37895808 Free PMC article.
Specificity to tumor tissue and bioavailability have been improved by co-encapsulating cisplatin and mifepristone in a liposomal formulation (L-Cis/MF), which needs further research to complete pre-clinical requirements. ...Additionally, the capacity of L-Cis/MF to …
Specificity to tumor tissue and bioavailability have been improved by co-encapsulating cisplatin and mifepristone in a liposomal form …
Mifepristone: clinical pharmacology.
Robbins A, Spitz IM. Robbins A, et al. Clin Obstet Gynecol. 1996 Jun;39(2):436-50. doi: 10.1097/00003081-199606000-00017. Clin Obstet Gynecol. 1996. PMID: 8734008 Review. No abstract available.
Pharmacokinetics of 10 mg of mifepristone.
Leminen R, Ranta S, von Hertzen H, Oehler J, Heikinheimo O. Leminen R, et al. Contraception. 2003 Dec;68(6):427-9. doi: 10.1016/s0010-7824(03)00181-1. Contraception. 2003. PMID: 14698072
The results of several randomized studies have verified the efficacy of 10 mg mifepristone in emergency contraception. In the present study we characterized the pharmacokinetics of 10 mg mifepristone. ...The pharmacokinetic data on 10 mg mifepristone a …
The results of several randomized studies have verified the efficacy of 10 mg mifepristone in emergency contraception. In the present …
Bioequivalence Study of Two Formulations of Mifepristone Tablets in Healthy Chinese Subjects Under Fasting Conditions.
Li M, Yi X, Fan L, Yang L, Xie S, Shentu J. Li M, et al. Clin Pharmacol Drug Dev. 2023 Sep;12(9):874-880. doi: 10.1002/cpdd.1249. Epub 2023 May 5. Clin Pharmacol Drug Dev. 2023. PMID: 37145969 Clinical Trial.
A single-dose, open-label, randomized, two-period crossover-design study was conducted to evaluate the bioequivalence of the reference and test formulations of mifepristone tablets. Each subject was randomized at the beginning to receive a 25-mg tablet of the test or the r …
A single-dose, open-label, randomized, two-period crossover-design study was conducted to evaluate the bioequivalence of the reference and t …
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.
Sarkar NN. Sarkar NN. Eur J Obstet Gynecol Reprod Biol. 2002 Mar 10;101(2):113-20. doi: 10.1016/s0301-2115(01)00522-x. Eur J Obstet Gynecol Reprod Biol. 2002. PMID: 11858883 Review.
Mifepristone-bound receptor dimers suppress transcription activation and thus, bring about anti-progestational activity that makes mifepristone a potential abortifacient and contraceptive agent. Clinical trials for termination of early pregnancy with 50-600 m …
Mifepristone-bound receptor dimers suppress transcription activation and thus, bring about anti-progestational activity that makes …
The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis.
Chen J, Wang J, Shao J, Gao Y, Xu J, Yu S, Liu Z, Jia L. Chen J, et al. Med Res Rev. 2014 Sep;34(5):979-1000. doi: 10.1002/med.21311. Epub 2014 Mar 1. Med Res Rev. 2014. PMID: 24585714 Review.
Current understanding of mechanism of action of mifepristone and its on-going clinical trials are changing our views on the drug beyond its abortifacient scope. ...We comprehensively analyze recent results from preclinical and clinical studies using mifepr …
Current understanding of mechanism of action of mifepristone and its on-going clinical trials are changing our views on the dr …
Determinations of mifepristone and its metabolites and their pharmacokinetics in healthy female Chinese subjects.
Teng YN, Dong RQ, Wang BJ, Liu HJ, Jiang ZM, Wei CM, Zhang R, Yuan GY, Liu XY, Guo RC. Teng YN, et al. Yao Xue Xue Bao. 2011 Oct;46(10):1241-5. Yao Xue Xue Bao. 2011. PMID: 22242458
The aim of this study is to establish an HPLC method for simultaneous determinations of mifepristone and its metabolites, mono-demethylated mifepristone, di-demethylated mifepristone and C-hydroxylated mifepristone in plasma and to evaluate the pharmac …
The aim of this study is to establish an HPLC method for simultaneous determinations of mifepristone and its metabolites, mono-demeth …
Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion.
Szpot P, Wachełko O, Jurek T, Zawadzki M. Szpot P, et al. Molecules. 2022 Nov 6;27(21):7605. doi: 10.3390/molecules27217605. Molecules. 2022. PMID: 36364430 Free PMC article.
Toxicological analysis of the mother's blood (collected the day after the pregnancy termination) revealed the presence of five compounds: mifepristone (557.4 ng/mL), N-desmethyl-mifepristone (638.7 ng/mL), 22-OH-mifepristone (176.9 ng/mL), N,N-didesmethyl- …
Toxicological analysis of the mother's blood (collected the day after the pregnancy termination) revealed the presence of five compounds: …
Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
Brogden RN, Goa KL, Faulds D. Brogden RN, et al. Drugs. 1993 Mar;45(3):384-409. doi: 10.2165/00003495-199345030-00007. Drugs. 1993. PMID: 7682909 Review.
Mifepristone is a potent oral antiprogestogen which acts at the level of the receptor, having a high affinity for the progesterone receptor. ...Mifepristone can also be used to induce labour in cases of intrauterine fetal death. Mifepristone has been shown to …
Mifepristone is a potent oral antiprogestogen which acts at the level of the receptor, having a high affinity for the progesterone re …
70 results